Cargando…
Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice
OBJECTIVE: Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in cancer treatment. Ang-2 has also been associated with rupture-prone atherosclerotic plaques in humans, suggesting a role for Ang-2 in plaque stability. Despite the availability of Ang-2 blocking age...
Autores principales: | Theelen, Thomas L., Lappalainen, Jari P., Sluimer, Judith C., Gurzeler, Erika, Cleutjens, Jack P., Gijbels, Marion J., Biessen, Erik A.L., Daemen, Mat J.A.P., Alitalo, Kari, Ylä-Herttuala, Seppo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549395/ https://www.ncbi.nlm.nih.gov/pubmed/26062989 http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.018 |
Ejemplares similares
-
SUR1-E1506K mutation impairs glucose tolerance and promotes vulnerable atherosclerotic plaque phenotype in hypercholesterolemic mice
por: Gurzeler, Erika, et al.
Publicado: (2021) -
Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression
por: Theodorou, Kosta, et al.
Publicado: (2017) -
Iron Oxide Nanoparticle Uptake in Mouse Brachiocephalic Artery Atherosclerotic Plaque Quantified by T(2)-Mapping MRI
por: Moonen, Rik P. M., et al.
Publicado: (2021) -
In vivo inhibition of nuclear factor of activated T-cells leads to atherosclerotic plaque regression in IGF-II/LDLR(–/–)ApoB(100/100) mice
por: Blanco, Fabiana, et al.
Publicado: (2018) -
Vascular Endothelial Growth Factor-B Induces a Distinct Electrophysiological Phenotype in Mouse Heart
por: Naumenko, Nikolay, et al.
Publicado: (2017)